EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 19 / No 10 (Octobre 2003) Med Sci (Paris), 19 10 (2003) 1011-1015 References
Free Access
Issue
Med Sci (Paris)
Volume 19, Number 10, Octobre 2003
Page(s) 1011 - 1015
Section M/S Revues
DOI https://doi.org/10.1051/medsci/200319101011
Published online 15 October 2003
  1. Sakett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine. How to practice and teach EBM. New York : Churchill Livingstone, 1997 : 250 p. [Google Scholar]
  2. Varughese PV, Carter AO. Meningococcal disease in Canada. Surveillance summary to 1987. Can Dis Wkly Rep 1989; 15 : 89–96. [Google Scholar]
  3. Ashton FE, Ryan JA, Borczyk A, Caugant DA, Mancino L, Huang D. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J Clin Microbiol 1991; 29 : 2489–93. [Google Scholar]
  4. Lavigne P, Boulianne N, Fortin C, Naccache H, Douville-Fradet M. Meningococcal infections in Quebec, 1991-1992. Can Commun Dis Rep 1992; 18 : 113–6. [Google Scholar]
  5. Frasch CE. Meningococcal vaccines : Past, present and future. In : Cartwright K, ed. Meningococcal disease. Chichester : John Wiley and Sons, 1995 : 245–83. [Google Scholar]
  6. Taunay AE, Feldman RA, Bastos CO, Galvao PAA, Morais JS, Castro IO. Avaliação do efeito protector de vacina polissacaridica antimenigococica da grupo C, em crianças de 6 a 36 meses. Rev Inst Adolfo Lutz 1978; 32 : 77–82. [Google Scholar]
  7. Direction de la protection de la santé publique. Bilan de la campagne de vaccination contre les infections à méningocoques. Décembre 1991 à avril 1993. Version initiale. Québec: Ministère de la Santé et des Services sociaux, 1994 : 176 p. [Google Scholar]
  8. De Wals P, Dionne M, Douville-Fradet M, Boulianne N, Drapeau J, De Serres G. Impact of a mass immunization campaign against serogroup C meningococcus in the province of Quebec, Canada. Bull WHO 1996; 74 : 407–11. [Google Scholar]
  9. Rivest P, Sagot B, Bédard L. Evaluation of the completeness of reporting of invasive meningococcal disease. Can J Publ Health 1999; 90 : 250–2. [Google Scholar]
  10. Yergeau A, Alain L, Pless R et al. Adverse events temporally associated with meningococcal vaccines. Can Med Assoc J 1996; 154 : 503–7. [Google Scholar]
  11. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec (Canada) 1990-1994. Clin Infect Dis 1998; 26 : 1159–64. [Google Scholar]
  12. Lebel MH, Tapiero BF, Saintonge F. Immunogenicity of bivalent AC polysaccharide meningococcal vaccine in children aged 6 through 24 months. JAMA 2001; 285 : 1578–9. [Google Scholar]
  13. De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001; 285 : 177–81. [Google Scholar]
  14. De Wals P, Erickson L. Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec. Vaccine 2002; 20 : 2840–4. [Google Scholar]
  15. Hubert B, Caugant DA. Recent changes in meningococcal disease in Europe. Eurosurveillance 1997; 10 : 1–4. (http://www.ceses.org/euro surv/v2n10/en15-221.htm). [Google Scholar]
  16. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992; 165 (suppl 1) : S49–52. [Google Scholar]
  17. Pollard AJ, Maiden MCJ. Meningococcal vaccines. Methods and protocols. Totowa, New Jersey : Humana Press, 2001 : 422 p. [Google Scholar]
  18. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK : a success story. Vaccine 2002; 20 : S58–67. [Google Scholar]
  19. Delbecq AL, Van de Ven AH, Gustafson DH. Group techniques for program planning : A guide to nominal group and Delphi processes. Glenview, Illinois : Scott, Foresman and Company, 1975. [Google Scholar]
  20. Comité sur l’immunisation du Québec. Évaluation du coût et des avantages potentiels d’une campagne d’immunisation contre le méningocoque de sérogroupe C au Québec. Québec: Institut de santé publique du Québec, 2001 : 1–20. (http://www.inspq.qc.ca). [Google Scholar]
  21. De Wals P, Allard MA, Guindon K, Mayrand L, Simard S, Black R. La vaccination contre le méningocoque est-elle utile ? Résultats d’une enquête dans la région de Sherbrooke. Can Commun Dis Rep 2002; 28 : 61–3. [Google Scholar]
  22. Comité sur l’immunisation du Québec. Pertinence de l’introduction du vaccin méningococcique dans le calendrier régulier d’immunisation au Québec. Québec: Institut de santé publique du Québec, 2002 : 1–16. (http://www.inspq.qc.ca). [Google Scholar]
  23. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to warrant adoption and utilization ? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146 : 473–81. [Google Scholar]
  24. Erickson LJ, De Wals P, Farand L. Equitable access to vaccination : Immunization program planning in Canada. Report presented to the Division of Immunization, Health Canada, Ottawa, May 22, 2001. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.